Filing Details

Accession Number:
0001209191-19-049533
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-13 18:51:59
Reporting Period:
2019-09-11
Accepted Time:
2019-09-13 18:51:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492426 Horizon Therapeutics Public Ltd Co HZNP Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1716059 Irina Konstantinovsky C/O Horizon Therapeutics Plc
Connaught House, 1St Fl, 1 Burlington Rd
Dublin L2 4
Evp, Chief Human Resources Off No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-09-11 16,014 $0.00 44,819 No 4 A Direct
Ordinary Shares Disposition 2019-09-11 7,095 $26.71 37,724 No 4 F Direct
Ordinary Shares Disposition 2019-09-12 17,838 $26.70 19,886 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Stock Units Disposition 2019-09-11 16,014 $0.00 16,014 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
32,028 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on August 14, 2019.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.52 to $26.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
  4. The restricted stock units vest in four annual installments of 16,014 shares, on each anniversary of the grant date (September 11, 2017).